Telix sets up subsidiary to make and trial radio-labelled meds in Japan

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Medicine

Radiopharmaceuticals firm Telix Pharmaceuticals Limited has established a subsidiary in Japan to support clinical development and manufacturing activities.

Melbourne, Australia-based Telix announced its new Kyoto operation this week, also revealing it has hired two executives - Shintaro Nishimura and Takeshi Oka - as president and chief medical officer, respectively.

CEO Christian Behrenbruch told in-Pharmatechnologist there is significant demand for Telix’s products in Japan, partly due to the country’s changing demographic profile.

As a market, Japan is probably the second largest homogeneous market after the US for our products.

There is a lot of government and academic momentum around radiopharmaceuticals in Japan, both diagnostic and therapeutic, given the aging nature of the population​,” he added.

Behrenbruch described Telix’s candidates as “targeted radiation products” explaining they can “both image and treat patients either by changing the dose or swapping the isotope on the same targeting agent​.”

Radiopharmaceutical manufacturing

In December, Telix formed a manufacturing partnership with JFE Engineering Corporation, a Yokohama-based engineering services firm that operates in the areas of energy and environment, urban infrastructure and industrial machinery.

The agreement will initially focus on the feasibility assessment for producing TLX-250 (girentuximab), an antibody-based agent for diagnosis of clear cell renal cell carcinoma, for the Japanese market.

According to Behrenbruch, “They (JFE) have built a state-of-the-art isotope production facility in Yokohama and we will be working with them closely to make our products available​.”

Related news

Show more

Related product

Follow us


View more